Further enhancement of the patent portfolio
Further enhancement of the patent portfolio
POLB 001 – a potential blockbuster immunomodulator
Key Senior Members of Former Amryt Pharma Leadership Team join Poolbeg Pharma Poolbeg team boosted by highly experienced executives with track record of success
Potential to address cancer treatment-related Cytokine Release Syndrome
1 November 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces that it will host a meeting for investors
Scientific Advisory Board Endorses Influenza Drug Targets Identified in AI Drug Discovery Programme
Poolbeg Pharma Partners with a Nasdaq-Listed Biopharma Company on its Oral Delivery Platform
Stifel’s Insight on hVIVO PLC
Positive results from influenza human challenge study conducted by hVIVO Pneumagen to advance antiviral candidate into further clinical studies
Positive Conclusion Reached in Immunomodulator I Patent Opposition Patent opposition hearing cancelled
Notice of allowance for patent grant in Japan